{"id":7341,"date":"2020-01-16T17:27:17","date_gmt":"2020-01-16T11:57:17","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7341"},"modified":"2021-07-24T12:57:45","modified_gmt":"2021-07-24T07:27:45","slug":"recent-pharma-happenings-for-lilly-nectar-23andme-almirall","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall","title":{"rendered":"Thumbs down to NKTR-181, Lilly expands its insulin armamentarium"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\"><strong>The US FDA has voted down Nektar Therapeutics\u2019 opioid painkiller\nNKTR-181, designed to treat lower back pain.&nbsp;<\/strong><\/h3>\n\n\n\n<p>The FDA\u2019s Anesthetic and Analgesic Drug Products Advisory\nCommittee and the Drug Safety and Risk Management Advisory Committee\nunanimously has decided not to recommend the use of the painkiller, taking into\naccount the opioid addiction.&nbsp;<\/p>\n\n\n\n<p><strong>NKTR-181<\/strong> (loxicodegol), a novel mu-opioid agonist, was designed to work on\nthe brain by entering into the cells slowly, with the company emphasizing on\nits ability to decrease the abuse. The company argued that by slowing down, the\nrate of the drug entering into cells would help to relieve pain without causing\neuphoria.&nbsp; However, the argument failed to please the committee members.\nThe committee feared the misuse and overuse of the opioid painkiller in the US\nwhere the problem of increasing opioid addition already prevails.&nbsp;<\/p>\n\n\n\n<p>After the setback, the company has withdrawn from investing into the development of the drug further to save on the cost factor which would lead to saving from USD 75 Million to USD 1.25 Million in the following year. Consequently, the shares of the company also plunged by 14.5%.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Eli Lilly has announced to sell Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen at rates half than their actual price. <\/strong><\/h3>\n\n\n\n<p>In its aim to make available cheaper Insulin to people, this is the second time, after it decided to do the same with its widely-used <a href=\"https:\/\/www.delveinsight.com\/report-store\/humalog-api-insights\">Humalog injection<\/a>&#8211; Lispro. Both the insulin products will now be sold at rates 50% cheaper than the price of branded versions.&nbsp;<\/p>\n\n\n\n<p>With the spur in diabetes prevalence and concerns over rising prices of insulin and other prescription drugs, the decision of the company to reduce the costs was somewhat expected. Recently, Nordisk and Sanofi also announced to lower down the price of their Insulin drug. However, the pharma players argue that the listed prices of the drugs are high due to the high cost of drug-making, and discounts and rebates paid to the insurers and healthcare managers.&nbsp;&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>23andMe has formed a collaboration with the Almirall, Spanish biotech for the development of its first drug.&nbsp;<\/strong><\/h3>\n\n\n\n<p>The company, 23andMe, focuses on developing an array of genetic\ntest kits, which can be used without any medical supervision.&nbsp;<\/p>\n\n\n\n<p>Through the deal,\nAlmirall will gain exclusive rights to develop and market 23andMe\u2019s bispecific\nmonoclonal antibody. The antibody is designed to target three different forms\nof the inflammatory cytokine, interleukin-36 (IL-36), indicated to treat people\nwith <a href=\"https:\/\/www.delveinsight.com\/blog\/psoriasis-pipeline-upcoming-psoriasis-treatments\/\">severe\npsoriasis<\/a>.&nbsp;<\/p>\n\n\n\n<p>The companies plan to advance for immune-dermatology therapy market and address the present unmet clinical needs. It would not be easy for 23andMe to enter into an already crowded <a href=\"https:\/\/www.delveinsight.com\/report-store\/severe-psoriasis-market\">psoriasis market <\/a>with pharma giants like AbbVie, Johnson &amp; Johnson, Eli Lilly, Amgen and many others occupying the significant chunk of the market. However, the company has a huge potential to fuel drug discovery with the help of its R&amp;D. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US FDA has voted down Nektar Therapeutics\u2019 opioid painkiller NKTR-181, designed to treat lower back pain.&nbsp; The FDA\u2019s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee unanimously has decided not to recommend the use of the painkiller, taking into account the opioid addiction.&nbsp; NKTR-181 (loxicodegol), a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7342,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17964,56,17546,831,228,2734,349,1444,17963,639,5586,5789],"industry":[17225],"therapeutic_areas":[17237,17227,17241],"class_list":["post-7341","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-23andme","tag-abbvie","tag-almirall","tag-amgen","tag-eli-lilly","tag-johnson-and-johnson","tag-latest-pharma-news","tag-nektar-therapeutics","tag-nktr-181","tag-pharma-news","tag-psoriasis-market","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-musculoskeletal"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NKTR-181 approval status; 23andMe&#039;s collaboration; Humalog&#039;s pricing<\/title>\n<meta name=\"description\" content=\"Eli Lilly has announced to sell Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen at rates half than their actual price.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NKTR-181 approval status; 23andMe&#039;s collaboration; Humalog&#039;s pricing\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly has announced to sell Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen at rates half than their actual price.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-16T11:57:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/16172206\/Pharma_news-16.01.2020.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NKTR-181 approval status; 23andMe's collaboration; Humalog's pricing","description":"Eli Lilly has announced to sell Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen at rates half than their actual price.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall","og_locale":"en_US","og_type":"article","og_title":"NKTR-181 approval status; 23andMe's collaboration; Humalog's pricing","og_description":"Eli Lilly has announced to sell Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen at rates half than their actual price.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-01-16T11:57:17+00:00","article_modified_time":"2021-07-24T07:27:45+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/16172206\/Pharma_news-16.01.2020.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall","name":"NKTR-181 approval status; 23andMe's collaboration; Humalog's pricing","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/16172206\/Pharma_news-16.01.2020.jpg","datePublished":"2020-01-16T11:57:17+00:00","dateModified":"2021-07-24T07:27:45+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Eli Lilly has announced to sell Humalog Mix75\/25 KwikPen and Humalog Junior KwikPen at rates half than their actual price.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lilly-nectar-23andme-almirall#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/16172206\/Pharma_news-16.01.2020.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/16172206\/Pharma_news-16.01.2020.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/16172206\/Pharma_news-16.01.2020-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">23andMe<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Almirall<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson and Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nektar Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NKTR-181<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Psoriasis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">23andMe<\/span>","<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Almirall<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Johnson and Johnson<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Nektar Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">NKTR-181<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Psoriasis market<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 16, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 16, 2020 5:27 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7341"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7341\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7342"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7341"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7341"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}